Silexion Therapeutics (SLXN) executive compensation, 2025 proxy

Ilan Hadar, Chief Executive Officer, was paid $1.5M in 2024, up 507% from $253,614 the year before.

Filed
June 16, 2025
Annual meeting
July 7, 2025
Pay year
2024
Named executives
3
CEO total pay
$1.5M+507% vs prior year
CEO pay in equity
77%$1.2M in awards
CFO total compensation
$770,0902024 total compensation
CSDO total compensation
$1,301,4902024 total compensation
Aggregate RSUs granted
78,650Directors and employees
Director RSUs
22,070Granted to directors
Available plan shares
63,953As of December 31, 2024

How Hadar was paid

$1.5M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary16%Stock awards77%All other compensation7%

Named executive officers

ExecutiveTotal
Ilan HadarChief Executive Officer$1,540,628
Mirit Horenshtein HadarChief Financial Officer$770,090
Dr. Mitchell ShirvanChief Scientific and Development Officer$1,301,490

What changed and why

  • $1.5M$1,540,628 Ilan Hadar total compensation in 2024, up from $253,614 in 2023.
  • $1.2M$1,192,785 in stock awards represented the largest component of the CEO’s 2024 compensation.
  • $447K$447,291 in stock awards were granted to CFO Mirit Horenshtein Hadar in 2024.
  • $1M$1,043,699 in stock awards were granted to Chief Scientific and Development Officer Mitchell Shirvan.
  • 78,650 RSUs were granted in aggregate to directors and employees upon consummation of the Business Combination.
  • All outstanding options and RSUs accelerated and became fully vested immediately before the Business Combination.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.